One Zyme provides AI‑driven agents tailored for biopharma professionals to streamline competitive intelligence, funding insight, and drug development research. By unifying siloed data and applying specialized natural‑language models, the platform delivers ranked shortlists of targets, partners, and investment opportunities, enabling users to quickly identify high‑value assets and strategic moves in both China and the US markets.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharma teams struggle to gather and analyze fragmented scientific, clinical, and financing data across regions, especially in fast‑moving markets like China and the US, leading to missed partnership and licensing opportunities.
Solution
One Zyme offers AI‑driven agents that ingest and unify siloed biopharma data into a searchable knowledge base. Users can define custom searches aligned with strategic priorities, and the AI returns ranked shortlists of companies, assets, or design variants (e.g., ligand, linker, isotope changes) with concise briefs and rationale. The platform highlights competitive intelligence such as trial starts, funding events, and scientific breakthroughs, ensuring users stay ahead of emerging competition. Integrated engagement tools help translate insights into warm introductions or targeted outreach.
Target Audience
Primary users are business development, corporate development, and investment teams within biopharma companies, CROs, CDMOs, and pharma‑focused investment banks seeking actionable intelligence on assets and partners.
Features
- AI agents customized for specific biopharma workflows (search, competitive intelligence, corporate development, CRO/CDMO business development)
- Unified data aggregation from scientific publications, clinical trial registries, and financing sources across China and the US
- Automatic inclusion of closely related design variants to avoid overlooking relevant candidates
- Relevance scoring and ranked shortlists with key facts (stage, region, partnering status, upcoming catalysts) and brief rationales
- Real‑time alerts on new trials, funding rounds, and preclinical breakthroughs
- Engagement module for warm introductions and personalized outreach to identified prospects